LSTA — Lisata Therapeutics Share News
0.000.00%
Last trade - 00:00- $30.60m
- $17.28m
- $0.17m
Brief: Lisata Therapeutics Announces Enhancements To Ongoing Phase 2B Ascend Trial Of LSTA1
Lisata Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Lisata Therapeutics Reports First Quarter 2023 Financial Results And Provides Business Update
Lisata Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: Lisata Therapeutics Says On May 1, Eliminated Position Of President & Chief Business Officer
Lisata Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: Lisata Therapeutics Receives $2.2 Million Of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
Brief: Lisata Therapeutics And Warpnine Announce First Patient Treated In The Ilsta Trial Of Lsta1
Brief: Lisata Therapeutics Inc Reports Quarterly Loss Per Share Of $0.76
Lisata Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview
Lisata Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview
Lisata Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Lisata Therapeutics Reports Third Quarter 2022 Financial Results And Provides Business Update
Lisata Therapeutics Inc expected to post a loss of 90 cents a share - Earnings Preview
Lisata Therapeutics Inc expected to post a loss of 90 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Johnson & Johnson, Altimmune, Twilio
Caladrius soars as stockholders approve merger with Cend Therapeutics
Brief: Caladrius Biosciences Announces Approval Of Merger And Name Change To Lisata Therapeutics
Brief: Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement With Roche